Looking forward: Here we have quite the gamble, as PSTTF is a very small company that has languished on the Australian exchange for years as a penny stock. However, this agent, PTX-200, could be very interesting, since it's a different kind of Akt inhibitor, a class of agents that has had a lot of difficulty in breast cancer overall. If its ongoing phase 2 trial manages to reproduce the data seen here (response rate of 50%) in a larger population, it could mean big things for the company.
